메뉴 건너뛰기




Volumn 53, Issue 12, 2015, Pages 1981-1990

Multi-analyte analysis of non-Vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry

Author keywords

liquid chromatography coupled tandem mass spectrometry (LC MS MS); matrix effects; non Vitamin K antagonist oral anticoagulants (NOACs); rivaroxaban overdose; therapeutic drug monitoring

Indexed keywords

ACETONITRILE; APIXABAN; DABIGATRAN; ENOXAPARIN; ION; RIVAROXABAN; STABLE ISOTOPE; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

EID: 84946854788     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-1108     Document Type: Article
Times cited : (22)

References (27)
  • 1
    • 84883273141 scopus 로고    scopus 로고
    • Treatment with novel oral anticoagulants: Indications, efficacy and risks
    • Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013;20:430-6.
    • (2013) Curr Opin Hematol , vol.20 , pp. 430-436
    • Ghanny, S.1    Crowther, M.2
  • 2
    • 84904727777 scopus 로고    scopus 로고
    • Edoxaban: An update on the new oral direct factor Xa inhibitor
    • Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014;74:1209-31.
    • (2014) Drugs , vol.74 , pp. 1209-1231
    • Bounameaux, H.1    Camm, A.J.2
  • 3
    • 84906354978 scopus 로고    scopus 로고
    • Non-Vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations
    • Saraf K, Morris P, Garg P, Sheridan P, Storey R. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgrad Med J 2014;90:520-8.
    • (2014) Postgrad Med J , vol.90 , pp. 520-528
    • Saraf, K.1    Morris, P.2    Garg, P.3    Sheridan, P.4    Storey, R.5
  • 4
    • 84904260419 scopus 로고    scopus 로고
    • New oral anticoagulants in practice: Pharmacological and practical considerations
    • Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 2014;14:175-89.
    • (2014) Am J Cardiovasc Drugs , vol.14 , pp. 175-189
    • Wang, Y.1    Bajorek, B.2
  • 5
    • 84905977363 scopus 로고    scopus 로고
    • Evolving use of new oral anticoagulants for treatment of venous thromboembolism
    • Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014;124:1020-8.
    • (2014) Blood , vol.124 , pp. 1020-1028
    • Yeh, C.H.1    Gross, P.L.2    Weitz, J.I.3
  • 6
    • 84922394366 scopus 로고    scopus 로고
    • Laboratory measurement of the anticoagulant activity of the non-Vitamin K oral anticoagulants
    • Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128-39.
    • (2014) J Am Coll Cardiol , vol.64 , pp. 1128-1139
    • Cuker, A.1    Siegal, D.M.2    Crowther, M.A.3    Garcia, D.A.4
  • 7
    • 84929998333 scopus 로고    scopus 로고
    • Newer clinically available antithrombotics and their antidotes
    • Levy S. Newer clinically available antithrombotics and their antidotes. J Interv Card Electrophysiol 2014;40:269-75.
    • (2014) J Interv Card Electrophysiol , vol.40 , pp. 269-275
    • Levy, S.1
  • 8
    • 84868210856 scopus 로고    scopus 로고
    • Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology
    • Baglin T, Keeling D, Kitchen S, British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427-9.
    • (2012) Br J Haematol , vol.159 , pp. 427-429
    • British Committee for Standards in Haematology1    Baglin, T.2    Keeling, D.3    Kitchen, S.4
  • 9
    • 84883238313 scopus 로고    scopus 로고
    • Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
    • Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110:543-9.
    • (2013) Thromb Haemost , vol.110 , pp. 543-549
    • Douxfils, J.1    Dogne, J.M.2    Mullier, F.3    Chatelain, B.4    Ronquist-Nii, Y.5    Malmstrom, R.E.6
  • 10
    • 84884861345 scopus 로고    scopus 로고
    • Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban
    • Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013;110:723-31.
    • (2013) Thromb Haemost , vol.110 , pp. 723-731
    • Douxfils, J.1    Tamigniau, A.2    Chatelain, B.3    Chatelain, C.4    Wallemacq, P.5    Dogne, J.M.6
  • 11
    • 84880838834 scopus 로고    scopus 로고
    • Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide
    • Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide. Thromb Haemost 2013;110:283-94.
    • (2013) Thromb Haemost , vol.110 , pp. 283-294
    • Douxfils, J.1    Chatelain, C.2    Chatelain, B.3    Dogne, J.M.4    Mullier, F.5
  • 12
    • 84930183306 scopus 로고    scopus 로고
    • Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry
    • Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 2014;36:597-605.
    • (2014) Ther Drug Monit , vol.36 , pp. 597-605
    • Gous, T.1    Couchman, L.2    Patel, J.P.3    Paradzai, C.4    Arya, R.5    Flanagan, R.J.6
  • 13
    • 84906734062 scopus 로고    scopus 로고
    • Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry
    • Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2014;100C:230-5.
    • (2014) J Pharm Biomed Anal , vol.100 C , pp. 230-235
    • Korostelev, M.1    Bihan, K.2    Ferreol, L.3    Tissot, N.4    Hulot, J.S.5    Funck-Brentano, C.6
  • 14
    • 84907863533 scopus 로고    scopus 로고
    • Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
    • Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014;12:1636-46.
    • (2014) J Thromb Haemost , vol.12 , pp. 1636-1646
    • Schmitz, E.M.1    Boonen, K.2    Van Den Heuvel, D.J.3    Van Dongen, J.L.4    Schellings, M.W.5    Emmen, J.M.6
  • 16
    • 0037663202 scopus 로고    scopus 로고
    • Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
    • Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019-30.
    • (2003) Anal Chem , vol.75 , pp. 3019-3030
    • Matuszewski, B.K.1    Constanzer, M.L.2    Chavez-Eng, C.M.3
  • 17
    • 78649392445 scopus 로고    scopus 로고
    • Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: Systematic investigation using ultrahigh-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization
    • Remane D, Meyer MR, Wissenbach DK, Maurer HH. Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultrahigh-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization. Rapid Commun Mass Spectrom 2010;24:3103-8.
    • (2010) Rapid Commun Mass Spectrom , vol.24 , pp. 3103-3108
    • Remane, D.1    Meyer, M.R.2    Wissenbach, D.K.3    Maurer, H.H.4
  • 18
    • 77949643951 scopus 로고    scopus 로고
    • Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures
    • Remane D, Wissenbach DK, Meyer MR, Maurer HH. Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures. Rapid Commun Mass Spectrom 2010;24:859-67.
    • (2010) Rapid Commun Mass Spectrom , vol.24 , pp. 859-867
    • Remane, D.1    Wissenbach, D.K.2    Meyer, M.R.3    Maurer, H.H.4
  • 20
    • 0003484310 scopus 로고    scopus 로고
    • Accessed on 26 June, 2014
    • Food and Drug Administration. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm. 2001. Accessed on 26 June, 2014.
    • (2001) Guidance for Industry, Bioanalytical Method Validation
  • 21
    • 84875253725 scopus 로고    scopus 로고
    • Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study
    • Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 2013;78-79:150-3.
    • (2013) J Pharm Biomed Anal , vol.78-79 , pp. 150-153
    • Delavenne, X.1    Mismetti, P.2    Basset, T.3
  • 22
    • 80255134514 scopus 로고    scopus 로고
    • UPLC MS/MS assay for routine quantification of dabigatran-A direct thrombin inhibitor-in human plasma
    • Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran-A direct thrombin inhibitor-in human plasma. J Pharm Biomed Anal 2012;58:152-6.
    • (2012) J Pharm Biomed Anal , vol.58 , pp. 152-156
    • Delavenne, X.1    Moracchini, J.2    Laporte, S.3    Mismetti, P.4    Basset, T.5
  • 23
    • 49849103069 scopus 로고    scopus 로고
    • Determination of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry
    • Rohde G. Determination of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;872:43-50.
    • (2008) J Chromatogr B Analyt Technol Biomed Life Sci , vol.872 , pp. 43-50
    • Rohde, G.1
  • 24
    • 0026580927 scopus 로고
    • MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
    • Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.
    • (1992) Comput Biol Med , vol.22 , pp. 155-163
    • Proost, J.H.1    Meijer, D.K.2
  • 25
    • 84882909945 scopus 로고    scopus 로고
    • Novel oral anticoagulants: Clinical pharmacology, indications and practical considerations
    • Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013;69:1617-33.
    • (2013) Eur J Clin Pharmacol , vol.69 , pp. 1617-1633
    • Harder, S.1    Graff, J.2
  • 26
    • 84881474743 scopus 로고    scopus 로고
    • Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations
    • Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187-94.
    • (2013) J Thromb Thrombolysis , vol.36 , pp. 187-194
    • Mani, H.1    Kasper, A.2    Lindhoff-Last, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.